NCT00520052View on ClinicalTrials.gov

Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

August 31, 2005

Conditions
Osteoporosis
Interventions
DRUG

zoledronic acid

5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)

Trial Locations (1)

CH48 5PE

Wirral Hospitals Universirt NHS Trust, Upton, Wirral

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Wirral University Teaching Hospital NHS Trust

OTHER